Retatrutide Weight Loss Results: What to Expect at 4, 12, and 24 Weeks (UAE Guide 2026)

Retatrutide Weight Loss Results: What to Expect at 4, 12, and 24 Weeks (UAE Guide 2026)

Retatrutide Weight Loss Results: What to Expect at 4, 12, and 24 Weeks (UAE Guide 2026)

Quick Summary
  • Week 1–4: Appetite reduction begins; 1–3% weight loss at starting dose
  • Week 4–12: Main fat-loss phase; expect 8–12% weight loss at 6–8mg dose
  • Week 12–24: Deep weight loss continues; 15–20% at adequate doses
  • Week 24–48: Approach plateau; 20–24% average at 12mg/week
  • Results vary — starting BMI, diet, and dose are the biggest variables

Setting realistic expectations is as important as the compound itself. UAE buyers searching for "retatrutide results" often encounter two extremes: exaggerated marketing claims and dismissive scepticism. The truth lies in the Phase 2 TRIUMPH trial data — one of the most rigorously conducted weight loss studies in recent medical history. This guide translates that data into a week-by-week timeline for UAE researchers, with practical context for life in Dubai.

24.2%Average at 48 weeks (12mg/week)
22.8%Average at 48 weeks (8mg/week)
17.3%Average at 48 weeks (4mg/week)

Phase 2 TRIUMPH Trial: The Weight Loss Timeline by Dose

The Phase 2 TRIUMPH trial published in the New England Journal of Medicine (Jastreboff et al., 2023) tested retatrutide across six dose arms over 48 weeks in adults with obesity. The data shows dose-dependent results with the clearest pattern: higher doses, greater loss — but all doses outperformed existing GLP-1 therapies.

Dose Week 12 Loss Week 24 Loss Week 36 Loss Week 48 Loss
1mg/week ~3% ~5% ~7% 8.7%
4mg/week ~8% ~12% ~15% 17.3%
8mg/week ~12% ~17% ~21% 22.8%
12mg/week ~14% ~19% ~23% 24.2%

Note: week-by-week figures are estimated from trial curves. Final 48-week values are from published results.

Realistic Week-by-Week Timeline for UAE Buyers

This is what most UAE researchers experience following the standard beginner escalation protocol (starting at 2mg, reaching 8mg by week 12):

Weeks 1–2
(2mg)
~0.5–1%

Appetite begins to reduce — you feel full faster and think about food less. Weight change is minimal at this dose. Side effects are most common here: mild nausea, especially after large meals. This is the adaptation phase.

Weeks 3–4
(2mg)
~1–2%

Noticeable appetite suppression. You may skip snacks automatically and find you are eating 20–30% less without effort. First visible changes begin to appear.

Weeks 5–8
(4mg)
~3–6%

Active fat-loss phase begins. The combination of GLP-1 satiety and GIP metabolic effects starts to compound. Most users report that meals feel satisfying at half their previous portion size. Nausea from the dose increase typically resolves by week 6–7.

Weeks 9–12
(6mg)
~8–12%

This is where results become clearly visible to others. Clothing fits differently. Most users are highly motivated at this stage. The glucagon receptor activation is now contributing meaningfully to energy expenditure — you may feel more energetic despite eating less.

Weeks 13–24
(8mg)
~14–18%

Sustained, steady loss continues. Most users find this dose to be their long-term sweet spot — effective results with manageable side effects. The rate of loss may slow slightly as your calorie deficit from lower intake becomes normalised.

Weeks 24–48
(8–12mg)
~20–24%

The deep loss phase. For those targeting maximum results and tolerating 12mg, the compound continues to work. Trial participants lost consistently through week 48 without plateauing at these doses, which distinguishes retatrutide from Ozempic's more rapid plateau.

Factors That Affect Your Results as a UAE Buyer

Clinical trial participants follow strict protocols: controlled diet, monitored lifestyle, consistent dosing. Real-world results in Dubai will vary based on:

Starting BMI and Total Weight

Percentage-based weight loss looks different at different starting weights. A person starting at 100kg losing 20% loses 20kg — a clear transformation. A person starting at 80kg loses 16kg at the same percentage. Higher starting BMI generally correlates with more pronounced early results.

Diet — Particularly for UAE Residents

The UAE diet is rich in refined carbohydrates (rice, bread), fats, and sugars — particularly at social and family gatherings. Retatrutide suppresses appetite strongly, but the type of calories consumed still matters. UAE users who reduce refined carbohydrates alongside retatrutide see the best results.

Ramadan: The UAE-Specific Variable

Many UAE users report their fastest weight loss during Ramadan while on retatrutide. The compound's appetite suppression combines powerfully with the daytime fast. Key considerations:

  • Inject at Iftar to align with food intake and minimise nausea during fasting hours
  • Avoid breaking the fast with large, rich meals — portion control remains important even with suppressed appetite
  • Hydrate aggressively during the Suhoor-to-Iftar window and after Iftar
  • Expect accelerated weight loss in Ramadan — adjust expectations for the following month

Dose Escalation Compliance

The biggest predictor of results is reaching an effective maintenance dose. Users who stay at 2mg because of nausea avoidance will see limited results. Those who follow the 4-week escalation schedule and reach 8–12mg consistently achieve the results shown in the trial data.

Heat and Exercise in Dubai

Dubai's extreme summer heat (June–September) can affect exercise capacity and appetite naturally. Retatrutide during summer may result in lower food intake than the already suppressed baseline — ensuring adequate protein intake (1.2–1.6g per kg body weight) is important to preserve muscle mass during aggressive weight loss.

Results Comparison: Retatrutide vs Other Weight Loss Methods

Method 12-Week Result 24-Week Result 48-Week Result
Retatrutide 12mg/week ~14% ~19% 24.2%
Retatrutide 8mg/week ~12% ~17% 22.8%
Mounjaro 15mg/week ~8% ~14% 22.5% (72 wks)
Ozempic 2.4mg/week ~6% ~10% 14.9% (68 wks)
Diet and exercise alone ~2–3% ~4–5% 5–7%

What Happens After You Stop Retatrutide?

Like all GLP-1 agonists, retatrutide's weight loss effect is maintained only while you continue dosing. Discontinuation leads to gradual appetite return and weight regain — typically at a rate of 1–2% per month in the first six months after stopping. This was observed with Ozempic and Mounjaro and is expected to behave similarly with retatrutide.

UAE buyers planning to stop should have a transition plan: gradual dose reduction, dietary habit maintenance, and increased exercise to offset the appetite return. Many users transition to a lower maintenance dose (4mg/week) rather than stopping entirely.

Start Your Retatrutide Protocol — Delivered Across UAE

Core Sup stocks retatrutide with third-party CoA. Same-day delivery to Dubai and Abu Dhabi.

Order Retatrutide at Core Sup

Related Guides

Research Compound Notice: Retatrutide is sold by Core Sup as a research compound for scientific research purposes only. It is not approved by the FDA, MOHAP, or equivalent regulatory agencies for human therapeutic use. Clinical data referenced: TRIUMPH Phase 2 (Jastreboff et al., NEJM 2023). Individual results will vary. This article does not constitute medical advice. Always consult a licensed medical professional before use.
Back to blog